Stoneridge Investment Partners LLC Invests $45,000 in Fractyl Health, Inc. (NASDAQ:GUTS)

Stoneridge Investment Partners LLC bought a new position in shares of Fractyl Health, Inc. (NASDAQ:GUTS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 21,618 shares of the company’s stock, valued at approximately $45,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GUTS. Renaissance Technologies LLC purchased a new stake in Fractyl Health during the 2nd quarter valued at approximately $61,000. SG Americas Securities LLC bought a new position in shares of Fractyl Health during the third quarter worth $33,000. Beta Wealth Group Inc. purchased a new position in Fractyl Health during the third quarter valued at $44,000. Massachusetts Financial Services Co. MA increased its holdings in Fractyl Health by 4.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after acquiring an additional 49,289 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Fractyl Health by 56.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock worth $204,000 after purchasing an additional 29,262 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley cut their price objective on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd.

Fractyl Health Stock Down 6.2 %

NASDAQ GUTS opened at $1.51 on Friday. The stock has a 50 day moving average price of $1.98 and a 200-day moving average price of $2.44. Fractyl Health, Inc. has a one year low of $1.51 and a one year high of $10.69. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. On average, equities analysts forecast that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Insider Buying and Selling

In other news, CEO Harith Rajagopalan sold 90,972 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $894,218.78. This trade represents a 15.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $1.81, for a total value of $40,446.26. Following the transaction, the insider now directly owns 153,544 shares in the company, valued at approximately $277,914.64. This represents a 12.70 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 274,032 shares of company stock worth $602,979.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.